Related Experiment Video
Updated: Sep 6, 2025

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Aortic stenosis in homozygous familial hypercholesterolaemia: a paradigm shift over a century
Alexandre M Bélanger1, Leo E Akioyamen2, Isabelle Ruel1
1Research Institute of the McGill University Health Centre, 1001, Boul. Décarie, Office EM1.2212, Montréal, Québec, Canada.
Homozygous familial hypercholesterolaemia (HoFH) patients show a decrease in aortic stenosis (AS) prevalence with statin use. The condition is shifting towards valvular aortic stenosis (VAS) due to improved survival from statins and apheresis.
Area of Science:
- Cardiovascular Medicine
- Genetics
- Pharmacology
Background:
- Homozygous familial hypercholesterolaemia (HoFH) is a severe genetic disorder characterized by extremely high LDL cholesterol levels, leading to premature atherosclerotic cardiovascular disease.
- Aortic stenosis (AS), including supravalvular (SVAS) and valvular (VAS) types, is a common comorbidity in HoFH patients.
- Currently, no medical treatments exist for AS in HoFH, with surgery being the only option for severe cases.
Purpose of the Study:
- To conduct a systematic review of current evidence on aortic stenosis (AS) in patients with Homozygous familial hypercholesterolaemia (HoFH).
- To determine the impact of pharmacological treatments, specifically statins, on the clinical presentation, phenotype, and clinical course of AS in HoFH over nine decades.
Main Methods:
- A comprehensive literature search was conducted across multiple databases (MEDLINE, Embase, Cochrane, PubMed, AfricaWide, Scopus) from inception to November 2021.
- Included studies were cross-sectional or retrospective, alongside individual case reports.
- Data from 424 HoFH cases were analyzed to compare AS prevalence and type between pre-statin and long-term statin eras.
Main Results:
- Aortic stenosis (AS) was identified in 57% of HoFH patients in the pre-statin era, compared to 35% in those reported more recently (post-2000).
- The ratio of supravalvular aortic stenosis (SVAS) to valvular aortic stenosis (VAS) shifted from 47:53 in patients not on statins to 10:90 in patients on long-term statin therapy.
- Increased longevity due to statins and lipoprotein apheresis was associated with this observed change in AS phenotype.
Conclusions:
- Supravalvular aortic stenosis (SVAS) and valvular aortic stenosis (VAS) are frequent manifestations in Homozygous familial hypercholesterolaemia (HoFH).
- The clinical phenotype of AS in HoFH appears to be shifting towards calcific valvular aortic stenosis (VAS).
- Improvements in survival through statin therapy and lipoprotein apheresis are associated with this evolving phenotype in HoFH patients.
Related Concept Videos
Atherosclerosis I: Introduction
Atherosclerosis III: Management
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Coronary Artery Disease II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cholesterol: Significance and Regulation
Considering cholesterol and...

